New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
16:24 EDTLPCNLipocine announces first patient dosed in Phase 2a study of LPCN 1111
Lipocine announced that the first patient has been dosed in a Phase 2a clinical study of LPCN 1111, a novel ester prodrug of testosterone, in hypogonadal males. The primary objectives of the study will be to determine safety, tolerability, single and steady state pharmacokinetics of testosterone following oral administration of LPCN 1111.
News For LPCN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 30, 2015
09:24 EDTLPCNLipocine comples LPCN 1021 Phase 3 clinical trial
Subscribe for More Information
April 24, 2015
08:48 EDTLPCNLipocine 4.65M share Spot Secondary priced at $6.50
Subscribe for More Information
April 23, 2015
16:01 EDTLPCNLipocine files to sell common stock, no amount given
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use